Fortis Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Fortis Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,485	Closed	-$1.35M	–	405
2025 Q4	$1.35M	Buy	+9,485	New	+$1.37M	0.2%	78
2025 Q1	–	Sell	-8,852	Closed	-$1.12M	–	283
2024 Q4	$1.12M	Buy	+8,852	New	+$1.09M	0.38%	54
2024 Q3	–	Sell	-8,113	Closed	-$1.12M	–	194
2024 Q2	$1.12M	Buy	8,113 +3,877	+92%	+$532K	0.4%	46
2024 Q1	$584K	Buy	+4,236	New	+$579K	0.25%	72

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fortis Capital Advisors's NBIX Position: Q1 2026 in Review

Fortis Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 9,485 shares — an estimated $1.35M sold.

Fortis Capital Advisors first reported a position in NBIX in Q1 2024 and held it in 4 quarters. The position peaked at $1.35M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Fortis Capital Advisors reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Fortis Capital Advisors sold 9,485 Neurocrine Biosciences shares in Q1 2026, an estimated $1.35M.
Fortis Capital Advisors first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 4 quarters.
Fortis Capital Advisors's Neurocrine Biosciences position peaked at $1.35M in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Fortis Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.